159 related articles for article (PubMed ID: 38923174)
1. Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.
Ahangar Davoodi M; Daneshmand MA; Rezaei T
J Diabetes; 2024 Jul; 16(7):e13570. PubMed ID: 38923174
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Fioretto P; Giaccari A; Sesti G
Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Yang Y; Pan H; Wang B; Chen S; Zhu H
Chin Med Sci J; 2017 Apr; 32(1):22-7. PubMed ID: 28399981
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
6. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
7. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
[TBL] [Abstract][Full Text] [Related]
8. Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus.
Tan K; Chow WS; Leung J; Ho A; Ozaki R; Kam G; Li J; Choi CH; Tsang MW; Chan N; Lee KK; Chan KW
Hong Kong Med J; 2019 Aug; 25(4):312-319. PubMed ID: 31416990
[No Abstract] [Full Text] [Related]
9. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
10. New Medications for the Treatment of Diabetes.
Garg SK; Giordano D
Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
[No Abstract] [Full Text] [Related]
11. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
13. A novel heterozygous mutation in the SLC5A2 gene causing severe glycosuria, mild failure to thrive, and subclinical hypoglycemia.
Papadimitriou DT; Manolakos E; Dermitzaki E; Filiousi F; Papoulidis I; Zoupanos G; Provenzano A; Mastorakos G
J Diabetes; 2021 Aug; 13(8):688-692. PubMed ID: 33893756
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of sodium glucose cotransporter-2 affects HbA1c levels in people with insulin-dependent diabetes mellitus and differing levels of glucagon.
Okada J; Yamada E; Okada S; Yamada M
Prim Care Diabetes; 2020 Oct; 14(5):570-571. PubMed ID: 31917118
[No Abstract] [Full Text] [Related]
15. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
16. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
17. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Kurozumi A; Okada Y; Tanaka Y
Endocr J; 2021 Mar; 68(3):361-369. PubMed ID: 33208570
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study.
Suzuki D; Yamada H; Yoshida M; Funazaki S; Amamoto M; Morimoto J; Hara K
J Diabetes Investig; 2020 Sep; 11(5):1230-1237. PubMed ID: 32100964
[TBL] [Abstract][Full Text] [Related]
19. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Vivian E
Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
